	Criteria	Brief description of now the criteria were nandled in the
D		meta-analysis
kep	oorting of background should inclu	
1	Problem definition	A link between Neurofibromatosis type 1 (NF1) and breast
		cancer has been suggested in several cohort and
		epidemiological studies and numerous cases of patients with
		NF1 presenting with breast cancer have been reported. The
		strength of the association between NF1 and the increased
		breast cancer risk remains uncertain due to the small study
		populations and differences in participants and
,		methodological methods used in the previous studies.
/	Hypothesis statement	Women with NF1 have a higher risk of breast cancer
		compared to the general population.
/	Description of study outcomes	Development of breast cancer
	Type of exposure or intervention	Diagnosis of NF1
	used	
	Type of study designs used	Observational study
	Study population	Women with NF1 and controls
Rep	oorting of search strategy should in	nclude
	Qualifications of searchers	The credentials of the investigators are provided in the author
	(eg, librarians and	list.
	investigators)	
	Search strategy, including	PubMed and PMC from oldest record to December 2015.
	time period included in the	
	synthesis and keywords	Key words: "Neurofibromatoses", "Neurofibromatosis 1",
		"genes, Neurofibromatosis 1", and "Neurofibromatosis type
		1" in combination with "breast neoplasms", "breast cancer",
		"malignancy", "neoplasm", "tumor", or "cancer."
		The search was restricted to studies in human beings and
		publications in English language.
	Effort to include all available	The references of all retrieved articles and recent reviews
	studies, including contact	were also manually reviewed.
	studies, including contact with authors	were also manually reviewed.
1	-	were also manually reviewed. PubMed and PMC
1	with authors	-
	with authors Databases and registries	
	with authors Databases and registries searched	PubMed and PMC
	with authors Databases and registries searched Search software used, name and version, including	PubMed and PMC
	with authors Databases and registries searched Search software used, name and version, including special features used (eg,	PubMed and PMC
1	with authors Databases and registries searched Search software used, name and version, including special features used (eg, explosion)	PubMed and PMC
√ √	with authors Databases and registries searched Search software used, name and version, including special features used (eg,	PubMed and PMC We did not employ the use of special search software.

Additional File 1. Meta-analysis of Observational Studies in Epidemiology (MOOSE) ChecklistCriteriaBrief description of how the criteria were handled in the

\checkmark	List of citations located and those excluded, including justification	Details of the literature search process are outlined in the flow chart.
V	Method of addressing articles published in languages other than English	The search was restricted to publications in English language
\checkmark	Method of handling abstracts and unpublished studies Description of any contact	The search was restricted to published studies and abstracts without full text and unpolished studies were excluded. No attempt was made to contact any authors.
Renor	with authors. rting of methods should include	
√	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	The inclusion criteria are presented in the "Study Selection" section.
N	Rationale for the selection and coding of data (eg, sound clinical principles or convenience)	The following data from each included study were extracted: first author, publication year, country, study design, sample size, number of cases / controls, diagnostic criteria, age at time of breast cancer diagnosis, follow-up duration, breast cancer stage at time of diagnosis, breast cancer subtype, development of bilateral breast cancer, development of other primary cancers, development of metastatic breast cancer, survival outcome, and effect sizes (SIR, RR, OR, HR) with 95% CI and adjusted factors.
\checkmark	Documentation of how data were classified and coded (eg, multiple raters, blinding, and inrerrater reliability)	Data were independently extracted and analyzed by two investigators and final decision was reached by consensus.
V	Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)	Table 2 presents the characteristics of studies included in the meta-analysis and adjustment factors for each study.
V	Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictiors of study results	The quality of each study was assessed using the Newcastle-Ottawa Scale.
\checkmark	Assessment of heterogeneity	I^2 statistic were used to explore the heterogeneity among studies.
V	Description of statistical methods (eg, complete description of fixed or random effects models,	Descriptions of statistical methods used are detailed in the "Statistical analysis" section.

	justification of whether the chosen models account for	
	predictors of study results, dose-response models, or	
	cumulative meta-analysis)	
	in sufficient detail to be	
	replicated	
\checkmark	Provision of appropriate	Two main tables and one supplemental table are provided.
	tables and graphics	One flow chart and two forest plots appear in the main text.
Repor	ting of results should include	
\checkmark	Graph summarizing individual study estimates	Figure 4
	and overall estimate	
\checkmark	Table giving descriptive	Table 2
	information for each study	
	included	
	Results of sensitivity testing	We performed a subgroup analysis based on two age groups
	(eg, subgroup analysis)	(< 50 or \ge 50 years of age). Given that a small number of
		studies were included in the meta-analysis, we were selective
		about what subgroups/other factors to examine. We did not
		have any drastically different studies that we might have
.1		wanted to exclude and check sensitivity of the estimates.
\mathcal{N}	Indication of statistical	95% confidence intervals are presented with all summary
Demon	uncertainty of findings	effect estimates.
Kepor	ting of discussion should includ Quantitative assessment of	Quantitative assessment of publication bias was not
	bias (eg, publication bias)	performed. Publication bias here would arise from either of
	onds (eg, publication onds)	these cohorts if they are published because of high rates of cancer or other cohorts are not published because of
		low/normal rates. Since we aren't evaluating a treatment
		effect, the suppression of null studies is less of a concern here.
		We also limited ourselves to these 4 studies to avoid potential
		publication bias from case studies/series. We could make a
		funnel plot; however, with only 4 studies, it would not be any more informative than the forest plot that we already present.
\checkmark	Justification for exclusion	The details of the exclusion of studies are shown in Flow
	(eg, exclusion of	chart.
	non-English-language	
	citations)	
\checkmark	Assessment of quality of included studies	Tables 2.
Repor	ting of conclusions should inclu	ıde
	Consideration of alternative	We discussed that we cannot exclude chance, residual or
	explanations for observed	unmeasured confounding as alternative explanation for our

	results	findings.
\checkmark	Generalization of the	We discussed that the results of current study suggests that
	conclusions (ie, appropriate	women with NF1 less than 50 years of age have a fivefold
	for the data presented and	increased risk of breast cancer, present with more advanced
	within the domain of the	disease, and may have an increased breast cancer related
	literature review)	mortality.
\checkmark	Guidelines for future	We discussed that a large multi-center, long-term, follow-up
	research	prospective study or a national initiative should be conducted
		to better delineate the true risk of breast cancer in NF1,
		understand the etiology and natural history of breast cancer in
		this population, and to determine the optimal screening
		method and timing to allow for earlier breast cancer diagnosis
		and decreased breast cancer associated morbidity and
		mortality in women with NF1.
\checkmark	Disclosure of funding source	The funding information is shown in the text.